Sector — Life Sciences & Healthcare
AI Advisory for Life Sciences & Healthcare
Life sciences AI carries some of the most complex compliance obligations in the EU AI Act. Getting classification right matters.
The regulatory complexity facing life sciences AI
Clinical AI needs a system-specific assessment. Article 6(1) covers AI that is a product or safety component under listed product legislation and requires third-party conformity assessment. The medical context alone does not classify every tool as high-risk. Providers and hospital deployers have different duties, with applicable transition dates to consider.
Key challenges for life sciences organisations
- High-risk AI classification under EU AI Act for diagnostic and clinical tools
- Regulatory overlap: EU AI Act, MDR, GDPR and HTA obligations
- AI governance frameworks for clinical and non-clinical AI use
- Vendor assessment for AI tools used in clinical pathways
- Board and leadership oversight of AI risk in patient-facing systems
Copilot and AI productivity in life sciences
Beyond clinical AI, Irish life sciences organisations have invested heavily in Microsoft Copilot and productivity AI. The challenge is the same as in other sectors: licences purchased but measurable productivity gains not realised. A recent life sciences engagement diagnosed the gap between Copilot investment and actual productivity impact — identifying the specific workflows where adoption was creating value and those where it was generating noise. The output was a structured adoption plan with measurable milestones, not a generic Copilot rollout guide.
Common questions
Is medical AI classified as high-risk under the EU AI Act?
Clinical AI needs a system-specific assessment. Article 6(1) covers AI that is a product or safety component under listed product legislation and requires third-party conformity assessment. The medical context alone does not classify every tool as high-risk. Providers and hospital deployers have different duties, with applicable transition dates to consider.
How does the EU AI Act interact with existing healthcare regulation in Ireland?
The EU AI Act adds a compliance layer on top of existing healthcare regulation — it does not replace GDPR, MDR, IVDR, or HIQA standards. In practice, a life sciences or healthcare organisation must satisfy all applicable frameworks simultaneously. The good news is that organisations that have already built compliance infrastructure for MDR or IVDR will have significant foundations to build from. The EU AI Act adds documentation, oversight, and registration requirements on top of what already exists — but it doesn't require starting from scratch. A readiness review maps the overlap and identifies the genuine gaps.
What AI governance does a pharmaceutical company need?
A pharmaceutical company using AI needs governance that covers both patient-facing AI (where EU AI Act high-risk obligations may apply) and operational AI (research tools, manufacturing optimisation, commercial analytics). The governance framework needs to distinguish between these categories, assign accountability for each system, and establish oversight mechanisms appropriate to the risk level. It also needs to be built for the regulatory environment in which the company operates — including GxP requirements where applicable. Our advisory is vendor-neutral: we work with your existing systems and obligations, not around a platform we want to sell you.
Book an AI Readiness Review
Vendor-neutral. Fixed-fee. Designed for regulated environments.